Advances in pharmacogenetics and pharmacogenomics

Journal of Clinical Pharmacology

Volumn 40, Issue 9, 2000, Pages 930-938

  Vesell, E S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANDROGEN; BERYLLIUM; CARRIER PROTEIN; CHLORAMPHENICOL; CORTICOSTEROID; COUMARIN ANTICOAGULANT; CYTOCHROME P450; DEXAMETHASONE; DRUG RECEPTOR; ENZYME; ESTROGEN; HALOTHANE; HEPATITIS B VACCINE; PHENYLTHIOUREA; RETINOIC ACID; VASOPRESSIN;

DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; GENETIC POLYMORPHISM; HISTORY OF MEDICINE; HUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; REVIEW; TREATMENT PLANNING;

EID: 0033668881     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022009666     Document Type: Review

References (51)

1. Genetic variation as a guide to drug development
2. Pharmacogenomics: Translating functional genomics into rational therapeutics
3. Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinical geneticist?
4. Studies in human inheritance IX: The inheritance of taste deficiency in man
5. Progressive oral gangrene probably due to lack of catalase in the blood (acatalasemia)
6. Drug reactions, enzymes, and biochemical genetics
7. Moderne probleme der humangenetik
8. Genetic control of drug levels in man: Phenylbutazone
9. Genetic control of drug levels in man: Antipyrine
10. Genetic control of dicumarol levels in man
11. Genetic control of phenobarbital-induced shortening of plasma antipyrine half-lives in man
12. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment
13. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity
14. Polymorphism of the cytochrome P450 CYP2D6 gene in a Europen population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution
15. Analysis of a structural polymorphism in the 5-HT(2A) receptor and clinical response to clozapine
16. No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population
17. Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia
18. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene
19. Systematic screening for mutations in the human serotonin-2A (5-HT(2A)) receptor gene: Identification of two naturally occurring receptor variants and association analysis in schizophrenia
20. Association between clozapine response and allelic variation in 5-HT(2A) receptor gene
21. Lack of allelic association between 102T/C polymorphism of serotonin receptor type 2A gene and schizophrenia in Chinese
22. An MspI polymorphism in the human serotonin receptor gene (HTR2): Detection by DGGE and RFLP analysis
23. No association between schizophrenia and the serotonin receptor 5HTR2a in an Italian population
24. Serotonin-6 receptor variant (C267T) and clinical response to clozapine
25. 2 receptor gene and tardive dyskinesia in schizophrenia
26. Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy
27. Cytologic evidence for gene amplification in methotrexate-resistant cells obtained from a patient with ovarian adenocarcinoma
28. Pharmacological rescue of mutant p53 conformation and function
29. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy
30. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
31. Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans
32. Comparative genomics and host resistance against infectious diseases
33. An RFLP map for 2q33-q37 from multicase mycobacterial and leishmanial disease families: No evidence for an Lsh/Ity/Bcg gene homologue influencing susceptibility to leprosy
34. Genetic control of susceptibility to leprosy in French Polynesia: No evidence for linkage with markers on telomeric human chromosome 21
35. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels
36. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels
37. Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy
38. Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy
39. Renal hemodynamic changes induced by captopril and angiotensin-converting enzyme gene polymorphism
40. Influence of the angiotensin II type I receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals
41. Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure
42. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
43. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease
44. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis
45. Influence of the genotype on the clinical course of the long-QT syndrome
46. MiRP1 forms l(Kr) potassium channels with HERG and is associated with cardiac arrhythmia
47. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
48. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
49. Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIa breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy